Skip to main content
WH

www.hiwemed.com

Inactive

Hiwemed develops vascular interventional embolization products that combine drug delivery systems with medical devices to treat conditions such as malignant tumors, uterine fibroids, and prostate enlargement. Their technology enables targeted vascular occlusion to effectively manage chronic diseases while minimizing surgical risks and recovery time for patients.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Many malignant tumors, uterine fibroids, and cases of prostate enlargement are treated with systemic therapies or major surgery, which can result in significant side effects and prolonged recovery times. Targeted drug delivery to the affected tissues is challenging, and current methods may not effectively occlude the blood vessels supplying these tissues.

Solution

Hiwemed develops drug-eluting embolic agents and microcatheters for targeted vascular occlusion in interventional radiology. Their products combine drug delivery systems with medical devices to treat conditions such as malignant tumors, uterine fibroids, and symptomatic prostate enlargement. The technology enables precise embolization of target vessels, starving the diseased tissue of its blood supply while simultaneously delivering therapeutic agents directly to the site. This approach aims to minimize systemic toxicity, reduce surgical risks, and shorten patient recovery times.

Target Audience

The primary customers are interventional radiologists, oncologists, and urologists who perform minimally invasive procedures to treat tumors, fibroids, and prostate enlargement.

Features

  • Drug-eluting microspheres for controlled release of chemotherapeutic agents or other drugs directly into the tumor microenvironment.
  • Hydrogel microspheres for precise and durable vascular occlusion.
  • Microcatheters designed for enhanced navigation and delivery of embolic agents to distal vessels.
  • Products indicated for transarterial chemoembolization (TACE) of liver tumors, bronchial artery embolization, uterine fibroid embolization (UFE), and prostatic artery embolization (PAE).
  • Minimally invasive procedures performed under image guidance (DSA, CT, MRI).
This profile is AI-generated and may contain inaccuracies.